BioCryst Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated July 25, 2025, discloses significant executive leadership changes at BioCryst Pharmaceuticals, Inc. (BCRX). The filing addresses the retirement of the current Chief Executive Officer and the appointment of a successor, along with related compensation arrangements and Board of Director adjustments.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and executive compensation details.
Material Changes and Executive Transitions
- CEO Retirement: Jon Stonehouse, President and CEO, notified the Board on July 25, 2025, of his intention to retire effective December 31, 2025. He will remain on the Board post-retirement.
- Succession Plan: Charlie Gayer was appointed President effective August 1, 2025, and will assume the role of CEO effective January 1, 2026.
- Board Expansion: The Board size will increase from nine to ten directors effective January 1, 2026, with Mr. Gayer elected to fill the new seat.
Compensation and Management Commentary
Outgoing CEO (Jon Stonehouse):
- Eligible for 2025 Annual Incentive Plan (AIP) payout subject to performance objectives.
- Receives subsidized group health coverage for up to 18 months following retirement.
- Cited no disagreement with the Board regarding operations or policies.
Incoming President/CEO (Charlie Gayer):
- President Role (Effective Aug 1, 2025): Annual base salary increased to $675,000. 2025 AIP target is 70% of base salary earned prior to Aug 1, and 75% of base salary earned from Aug 1 through Dec 31.
- CEO Role (Effective Jan 1, 2026): Expected annual base salary of $775,000 with an AIP target of 85% of base salary.
- Severance Benefits (CEO Role): In the event of termination without cause or constructive termination following a change of control, benefits include two years of base salary, two times the target incentive compensation (paid over two years), and up to 12 months of subsidized health coverage.
Investor Verification Checklist
- Verify the exact effective dates for Mr. Gayer's transition from President to CEO (Aug 1, 2025 vs. Jan 1, 2026).
- Review the specific performance objectives required for Mr. Stonehouse to receive his 2025 AIP payout.
- Confirm the terms of the new employment agreement for Mr. Gayer's CEO role, specifically the severance triggers and calculation methods.
- Monitor the Board composition changes effective January 1, 2026, and Mr. Gayer's committee assignments.